A comparative clarithromycin bioavailability study: Determination of clarithromycin and 14-(R)-hydroxyclarithromycin under fasting and fed conditions

International Journal of Clinical Pharmacology and Therapeutics

Volumn 42, Issue 6, 2004, Pages 342-349

  Benninger, P ^a   Cooper, A ^a   Moisan, R ^a   Patel, P ^a   Thiessen, J J ^b  

^a Alllied Clinical Research   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

14 (R) hydroxyclarithromycin; Bioavailability; Bioequivalence; Clarothromycin; Fasting; Fed; Female; Male

Indexed keywords

14 HYDROXYCLARITHROMYCIN; CLARITHROMYCIN; GENERIC DRUG;

ACCURACY; ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MEDICAL ASSESSMENT; NORMAL HUMAN; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE;

EID: 2942720672     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP42342     Document Type: Article

References (10)

1. Blume HH, Midha KK 1993 Bio-Intemational 92, conference on bioavailability, bioequivalence, and pharmacokinetic: studies. J Pharm Sci 82: 1186-1189
2. Chu SY, Park Y, Locke C, Wilson DS, Cavanaugh JC 1992a Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 32: 32-36
3. Chu SY, Deaton RL, Cavanaugh JC 1992b Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 36: 1147-1150
4. Chu SY, Wilson DS, Deaton RL, Mackenthun AV, Eason CN, Cavanaugh JC 1993 Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 33: 719-726
5. Ferrero JL, Bopp BA, Marsh KC, Quigley SC, Johnson MJ, Anderson DJ, Lamm JE, Tolman KG, Sanders SW Cavanaugh JC et al 1990 Metabolism and disposition of clarithromycin in man. Drug Metab Disp 18: 441-446
6. Goldman RC, Zakula D, Flamm R, Beyer J, Capobianco J 1994 Tight binding of clarithromycin, its 14-(R)hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. Antimicrob Agents Chemother 38: 1496-1500
7. Hardy DJ, Guay DR, Jones RN 1992 Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview. Diag Microbiol Infect Dis 15: 39-53
8. Hoover WW Barrett MS, Jones RN 1992 Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclaridiromycin. Diag Microbiol Infect Dis 15: 259-266
9. Kim YG, Kim HJ, Kwon JW, Kim WB, Lee MG 2001 Bioequivalence of clarithromycin tablet formulations assessed in Korean males. Int J Clin Pharmacol Ther 39: 356-361
10. Lerner FE, Caliendo G, Santagada V Santana GSM, Moraes MEA, De Nucci G 2000 Clarithromycin bioequivalence study of two oral formulations in healthy human volunteers. Int J Clin Pharmacol Ther 38: 345-354